JP2018504445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504445A5 JP2018504445A5 JP2017541786A JP2017541786A JP2018504445A5 JP 2018504445 A5 JP2018504445 A5 JP 2018504445A5 JP 2017541786 A JP2017541786 A JP 2017541786A JP 2017541786 A JP2017541786 A JP 2017541786A JP 2018504445 A5 JP2018504445 A5 JP 2018504445A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- trypsin inhibitor
- oral administration
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 7
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 7
- 239000002753 trypsin inhibitor Substances 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims 4
- 229960001319 parathyroid hormone Drugs 0.000 claims 4
- 239000000199 parathyroid hormone Substances 0.000 claims 4
- 244000068988 Glycine max Species 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010039627 Aprotinin Proteins 0.000 claims 1
- 244000045232 Canavalia ensiformis Species 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108010064983 Ovomucin Proteins 0.000 claims 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims 1
- 108010049264 Teriparatide Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000013022 formulation composition Substances 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
- 229960005460 teriparatide Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128296A JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113625P | 2015-02-09 | 2015-02-09 | |
| US201562113604P | 2015-02-09 | 2015-02-09 | |
| US201562113600P | 2015-02-09 | 2015-02-09 | |
| US201562113629P | 2015-02-09 | 2015-02-09 | |
| US201562113619P | 2015-02-09 | 2015-02-09 | |
| US201562113638P | 2015-02-09 | 2015-02-09 | |
| US201562113673P | 2015-02-09 | 2015-02-09 | |
| US62/113,638 | 2015-02-09 | ||
| US62/113,600 | 2015-02-09 | ||
| US62/113,673 | 2015-02-09 | ||
| US62/113,625 | 2015-02-09 | ||
| US62/113,619 | 2015-02-09 | ||
| US62/113,629 | 2015-02-09 | ||
| US62/113,604 | 2015-02-09 | ||
| PCT/IL2016/050151 WO2016128970A1 (en) | 2015-02-09 | 2016-02-09 | Treatment of hypoparathyroidism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128296A Division JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504445A JP2018504445A (ja) | 2018-02-15 |
| JP2018504445A5 true JP2018504445A5 (enExample) | 2019-03-07 |
| JP6925970B2 JP6925970B2 (ja) | 2021-08-25 |
Family
ID=56614456
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541786A Active JP6925970B2 (ja) | 2015-02-09 | 2016-02-09 | 副甲状腺機能低下症の治療 |
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Active JP7775239B2 (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Active JP7775239B2 (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20180028622A1 (enExample) |
| EP (5) | EP3256153A4 (enExample) |
| JP (6) | JP6925970B2 (enExample) |
| CN (5) | CN114949185A (enExample) |
| CA (5) | CA3011654A1 (enExample) |
| HK (5) | HK1247838A1 (enExample) |
| IL (7) | IL303216A (enExample) |
| MX (2) | MX2017010220A (enExample) |
| WO (5) | WO2016128971A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| CA2832811A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
| AU2014261336B2 (en) | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| CN114949185A (zh) | 2015-02-09 | 2022-08-30 | 安特拉贝欧有限公司 | 骨质疏松症的治疗 |
| NZ751668A (en) * | 2016-08-17 | 2022-07-29 | Entera Bio Ltd | Formulations for oral administration of active agents |
| BR112020014624A2 (pt) * | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| TWI821541B (zh) * | 2019-03-08 | 2023-11-11 | 奧孟亞股份有限公司 | Pth類似物之口服製劑及治療 |
| CA3152944A1 (en) * | 2019-09-03 | 2021-03-11 | Amgen Inc. | Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof |
| CN114306249A (zh) * | 2020-09-28 | 2022-04-12 | 深圳翰宇药业股份有限公司 | 一种特立帕肽冻干药物组合物及其制备方法 |
| US12251208B2 (en) * | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| CN114288388B (zh) * | 2022-01-25 | 2023-11-03 | 华中科技大学同济医学院附属协和医院 | 网膜素在制备炎症性肠病治疗药物中的应用 |
| MX2024010389A (es) * | 2022-02-24 | 2024-09-04 | Entera Bio Ltd | Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral de hormona paratiroidea. |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| WO2023161935A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone |
| CA3251865A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd | FORMULATIONS COMPRISING AN ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-TYPE PEPTIDE-2 |
| JP2025506821A (ja) * | 2022-02-24 | 2025-03-13 | エンテラ バイオ エルティーディー． | 活性薬剤の経口投与用の酸中和ポリマーを含む製剤 |
| EP4482514A1 (en) * | 2022-02-24 | 2025-01-01 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-1 and analogs thereof |
| WO2023161938A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide |
| WO2025046590A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations for oral administration of active agents |
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
| WO2025146144A1 (zh) * | 2024-01-05 | 2025-07-10 | 成都国为生物医药有限公司 | 一种地非法林的口服药物组合物 |
| US12466883B1 (en) | 2024-05-13 | 2025-11-11 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360793A (en) * | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
| CN1162917A (zh) * | 1994-10-07 | 1997-10-22 | 伯温德药品服务公司 | 肠内涂层组合物，用其涂覆的方法和涂覆制品 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| CA2220301C (en) * | 1995-06-02 | 2006-02-21 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
| JP3880093B2 (ja) | 1995-08-08 | 2007-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 錠剤 |
| JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| WO1998009645A1 (en) | 1996-09-04 | 1998-03-12 | Dott Research Laboratory | Peptide-containing drug compositions for oral administration |
| CA2290443A1 (en) | 1997-05-14 | 1998-11-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Peptide parathyroid hormone analogs |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| WO2000048589A1 (en) * | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| EP1163209A4 (en) | 1999-02-26 | 2004-12-29 | Emisphere Tech Inc | COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS |
| DE60017888T2 (de) | 1999-04-05 | 2006-01-19 | Emisphere Technologies, Inc. | Dinatrium-salze, monohydrate und ethanol-solvate |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| WO2001032130A2 (en) | 1999-11-05 | 2001-05-10 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| AU2226901A (en) * | 1999-12-28 | 2001-07-09 | Ajinomoto Co., Inc. | Oral preparations for diabetes |
| ATE443527T1 (de) * | 2001-08-17 | 2009-10-15 | Novartis Pharma Gmbh | 5-cnac zur oralen verabreichung von parathormonfragmenten |
| MXPA04004567A (es) | 2001-11-13 | 2004-09-10 | Emisphere Tech Inc | Compuestos y composiciones de fenoxi amina para adminstrar agentes activos. |
| US20040259952A1 (en) * | 2001-11-29 | 2004-12-23 | Richat Abbas | Formulations for oral administration of cromolyn sodium |
| CN1606434A (zh) | 2001-12-19 | 2005-04-13 | 株式会社三和化学研究所 | 控制释放成型品 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
| JP2007525472A (ja) * | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| JP2005281231A (ja) | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| EP1781257B1 (en) | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| NZ555244A (en) | 2004-11-19 | 2010-06-25 | Smithkline Beecham Corp | Manufacture process for pharmaceutical product allowing delivery of a plurality of active agents |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| ES2540929T3 (es) | 2005-02-01 | 2015-07-14 | Emisphere Technologies, Inc. | Sistema de administración de retención gástrica y liberación controlada |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| JP5123471B2 (ja) | 2005-08-18 | 2013-01-23 | 帝人ファーマ株式会社 | 用量調整が容易な製剤 |
| CA2621577C (en) | 2005-09-06 | 2013-12-24 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US20080255048A1 (en) | 2005-11-17 | 2008-10-16 | Moise Azria | Pharmaceutical Composition |
| US20070178155A1 (en) * | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8703821B2 (en) | 2006-04-18 | 2014-04-22 | Emisphere Technologies Inc. | Dialkyl ether delivery agents |
| JP4642115B2 (ja) * | 2006-12-12 | 2011-03-02 | 株式会社堀場エステック | 流量比率制御装置 |
| EP2380564B1 (en) | 2007-04-04 | 2014-10-22 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
| WO2008132727A2 (en) | 2007-04-26 | 2008-11-06 | Technion Research And Development Foundation Ltd | Oral delivery of proteins and peptides |
| CN101801353A (zh) * | 2007-09-11 | 2010-08-11 | 奥拉黑尔斯公司 | 具有用于治疗咽喉、食管和胃的局部活性成分的粘附性锭剂 |
| WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
| IT1393244B1 (it) | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| RU2494755C2 (ru) * | 2008-08-18 | 2013-10-10 | Интера Био Лтд. | Способы и композиции для перорального введения белков |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| AU2011239935A1 (en) | 2010-04-16 | 2012-11-08 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| RU2600440C3 (ru) * | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| WO2013032934A1 (en) | 2011-08-26 | 2013-03-07 | Aegis Therapeutics, Llc | Compositions and methods thereof for oral administration of drugs |
| WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
| CN114949185A (zh) | 2015-02-09 | 2022-08-30 | 安特拉贝欧有限公司 | 骨质疏松症的治疗 |
| NZ751668A (en) | 2016-08-17 | 2022-07-29 | Entera Bio Ltd | Formulations for oral administration of active agents |
| JP7419862B2 (ja) | 2020-02-14 | 2024-01-23 | 株式会社リコー | 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置 |
-
2016
- 2016-02-09 CN CN202210601969.9A patent/CN114949185A/zh active Pending
- 2016-02-09 WO PCT/IL2016/050152 patent/WO2016128971A1/en not_active Ceased
- 2016-02-09 EP EP16748833.7A patent/EP3256153A4/en active Pending
- 2016-02-09 CA CA3011654A patent/CA3011654A1/en active Pending
- 2016-02-09 HK HK18107372.3A patent/HK1247838A1/zh unknown
- 2016-02-09 IL IL303216A patent/IL303216A/en unknown
- 2016-02-09 IL IL283258A patent/IL283258B2/en unknown
- 2016-02-09 JP JP2017541786A patent/JP6925970B2/ja active Active
- 2016-02-09 EP EP16748831.1A patent/EP3256113B1/en active Active
- 2016-02-09 CA CA2975578A patent/CA2975578A1/en active Pending
- 2016-02-09 IL IL292417A patent/IL292417B2/en unknown
- 2016-02-09 CA CA3011657A patent/CA3011657A1/en active Pending
- 2016-02-09 JP JP2017541780A patent/JP6925969B2/ja active Active
- 2016-02-09 CN CN202111014352.9A patent/CN113713090B/zh active Active
- 2016-02-09 WO PCT/IL2016/050155 patent/WO2016128974A1/en not_active Ceased
- 2016-02-09 CN CN201680016126.5A patent/CN107427481A/zh active Pending
- 2016-02-09 IL IL253802A patent/IL253802B/en unknown
- 2016-02-09 HK HK18107250.0A patent/HK1247822A1/zh unknown
- 2016-02-09 US US15/549,425 patent/US20180028622A1/en active Pending
- 2016-02-09 CA CA2975710A patent/CA2975710C/en active Active
- 2016-02-09 HK HK18107403.6A patent/HK1247843A1/zh unknown
- 2016-02-09 CN CN202111014634.9A patent/CN113730556A/zh active Pending
- 2016-02-09 CN CN202111014609.0A patent/CN113694190B/zh active Active
- 2016-02-09 WO PCT/IL2016/050153 patent/WO2016128972A1/en not_active Ceased
- 2016-02-09 US US15/549,442 patent/US20180050096A1/en not_active Abandoned
- 2016-02-09 US US15/549,436 patent/US10583177B2/en active Active
- 2016-02-09 HK HK18107251.9A patent/HK1247823A1/zh unknown
- 2016-02-09 EP EP16748832.9A patent/EP3256152A4/en active Pending
- 2016-02-09 US US15/549,394 patent/US20180036382A1/en active Pending
- 2016-02-09 CA CA2975676A patent/CA2975676A1/en active Pending
- 2016-02-09 EP EP16748834.5A patent/EP3256114A4/en active Pending
- 2016-02-09 MX MX2017010220A patent/MX2017010220A/es unknown
- 2016-02-09 HK HK18107355.4A patent/HK1247835A1/zh unknown
- 2016-02-09 US US15/549,418 patent/US20180036234A1/en active Pending
- 2016-02-09 WO PCT/IL2016/050151 patent/WO2016128970A1/en not_active Ceased
- 2016-02-09 WO PCT/IL2016/050154 patent/WO2016128973A1/en not_active Ceased
- 2016-02-09 EP EP16748835.2A patent/EP3256149A4/en active Pending
- 2016-02-09 IL IL292218A patent/IL292218B2/en unknown
-
2017
- 2017-08-02 IL IL253804A patent/IL253804B/en unknown
- 2017-08-02 IL IL253803A patent/IL253803B/en active IP Right Grant
- 2017-08-08 MX MX2022014313A patent/MX2022014313A/es unknown
-
2019
- 2019-12-23 US US16/724,400 patent/US12076373B2/en active Active
-
2021
- 2021-08-04 JP JP2021128296A patent/JP2021176914A/ja active Pending
- 2021-08-04 JP JP2021128281A patent/JP7275207B2/ja active Active
-
2023
- 2023-02-06 JP JP2023015960A patent/JP7775239B2/ja active Active
- 2023-05-10 JP JP2023078011A patent/JP2023100920A/ja active Pending
-
2024
- 2024-02-05 US US18/432,185 patent/US20240181020A1/en active Pending
- 2024-08-09 US US18/798,864 patent/US20240398904A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504445A5 (enExample) | ||
| JP2018504444A5 (ja) | 医薬組成物 | |
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
| JP2015515459A5 (enExample) | ||
| WO2009095226A3 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
| JP2014129360A5 (enExample) | ||
| RU2015139742A (ru) | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| WO2006010423A3 (en) | Azaindole inhibitors of mtp and apob | |
| CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
| JP2016505613A5 (enExample) | ||
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| JP2018527305A5 (enExample) | ||
| WO2012020301A3 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| CL2013002129A1 (es) | Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras. | |
| WO2016118040A8 (ru) | Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| RU2013157398A (ru) | Композиция | |
| CL2004002030A1 (es) | Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata | |
| HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
| EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст |